



POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Mastrodonato and Braguti Confirmation No.: 8421
Serial No.: 10/080,736 Group Art Unit: 1623
Filed: February 22, 2002 Examiner: Michael C. Henry
For: COMPOSITIONS AND METHODS FOR THE Attorney Docket No.: 11109-004
TREATMENT OR PREVENTION OF
INFLAMMATION

REVOCATION AND POWER OF ATTORNEY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Sinclair Pharmaceuticals, Ltd. hereby revokes all previous powers of attorney and appoints:

Practitioners at Customer Number 20583

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

The above mentioned Customer Number.

Practitioners at Customer Number 20583.

Firm or Individual Name:

Address: Jones Day
222 East 41st Street
New York, New York 10017

Telephone: (212) 790-2803

Statement Under 37 C.F.R. 3.73(b)

Sinclair Pharmaceuticals, Ltd. states that it is:

the assignee of the entire right, title, and interest; or
 an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is %

in the patent application/patent identified above by virtue of either:

An assignment from inventors Marco Mastrodonato and Gianluca Braguti to Sinclair Pharmaceuticals, Ltd. of the patent application/patent identified above was recorded in the United States Patent and Trademark Office on June 7, 2002 at Reel 012994, Frame 0630.


A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.
[Note: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: Sinclair Pharmaceuticals, Ltd.

Date: 21st January 2004 Signature: 
Typed Name: Jerry Randall
Position/Title: Chief Financial Officer

Note: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required.

Total of _____ forms are submitted.